When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a new layer of information,” specifically ...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results